

## INVITED REVIEW

# Fibrinogen, a possible key player in Alzheimer's disease

M. CORTES-CANTELI and S. STRICKLAND

Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY, USA

**To cite this article:** Cortes-Canteli M, Strickland S. Fibrinogen, a possible key player in Alzheimer's disease. *J Thromb Haemost* 2009; 7 (Suppl. 1): 146–50.

**Summary.** Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive loss of cognitive function and subsequent death. Since the first case of this disease was diagnosed one century ago, much effort has been dedicated to find a cure. However, even though progress has been made in the knowledge of the pathogenesis of this disease, an effective treatment has not been found. Therefore, new approaches are needed urgently. AD patients have an abnormal cerebral vasculature and brain hypoperfusion, and a large body of research, including some from our lab, implicates cerebrovascular dysfunction as a contributing factor to AD. Reducing fibrinogen, a circulating protein critical in hemostasis, provides a significant decrease in the neurovascular damage, blood–brain barrier permeability and neuroinflammation present in AD. These studies implicate fibrinogen as a possible contributor to AD.

**Keywords:** Alzheimer's disease, blood–brain barrier, fibrinogen, neurovascular damage.

## Introduction

AD is the leading cause of dementia in the elderly with approximately 18 million people affected worldwide. This number is increasing due to an aging population. The early symptoms of AD, memory loss and general cognitive decline, are due to loss of neurons in the hippocampus and cortex. Despite the two-well established and classical diagnostic features of AD, the extracellular neuritic plaques and the intracellular neurofibrillary tangles [1], the precise cause of neuronal death is not known. Although progress has been made in the molecular and cellular understanding of the pathogenesis of AD [2,3], numerous clinical trials have failed [4] and there are only five drugs approved which have minor effects on disease progression [5]. This lack of an effective treatment for AD has promoted the search of other theories besides brain deposition of amyloid as the main cause of this neurodegenerative disease. There is significant evidence that AD patients suffer from inadequate circulation and cerebro-

vascular pathology, and one theory that is gaining evidence is the importance of vascular factors in the onset and progression of this disease [6–8].

## Amyloid hypothesis

The extracellular plaques in the AD brain are composed primarily of a 40–42 amino acid peptide called the amyloid- $\beta$  peptide (A $\beta$ ) that is proteolytically derived from the amyloid- $\beta$  precursor protein (APP). The A $\beta$  peptide is normally soluble, but it can aggregate depositing as plaques in the brain parenchyma and as cerebral amyloid angiopathy (CAA) in the blood vessels [9]. There is substantial evidence that A $\beta$  is involved in the pathology of AD [10]. For example, all of the rare human mutations that lead to early onset familial AD involve mutations that lead to increased expression of APP or increased generation or fibrillization of A $\beta$  via the  $\gamma$ -secretase pathway. Transgenic mice that over-express human APP develop A $\beta$  plaques, inflammation, and cognitive deficiencies [11–13]. Although A $\beta$  is clearly implicated in AD, it is not understood how this peptide induces neuronal death or cognitive deficits. Different AD animal models have been immunized against A $\beta$  and a cognitive improvement has been detected, even in the absence of a decrease in the A $\beta$  load [14]. Numerous clinical trials in humans are in progress [15], but the first one of immunization against A $\beta$  failed [16]. In addition, the extracellular amyloid plaques do not correlate well with severity of dementia, and it is likely that oligomers, the small precursor of these insoluble deposits, have a principal role perturbing some other brain property [17].

## Vascular disease in AD

### Cerebrovascular dysfunction

The cerebrovascular structure and function in the AD brain are damaged and the brain is especially susceptible to interruptions in blood flow as it has a high demand for oxygen and glucose and almost no long-term energy stores [6]. A decrease in cerebral blood flow has been reported in AD patients and, furthermore, a correlation between the level of cerebral hypoperfusion and the degree of dementia has been identified [6]. Besides the cortical and leptomeningeal vessels affected by the deposition of A $\beta$  as CAA (see below), the

Correspondence: Sidney Strickland, Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY 10065, USA.  
Tel.: 212 327 8705; fax: 212 327 8774.  
E-mail: Strickland@rockefeller.edu

microvasculature also presents abnormalities that include irregular shape, degeneration and atrophy of the smooth muscle cells, pericytes and endothelial cells as well as swollen glial end feet [6]. All these affected structures are part of the neurovascular unit, a structure composed by neurons, astrocytes and vascular cells which functions in maintenance of brain hemostasis and the defense against brain injury [7,18]. Consistent with these findings, studies of AD mice show early endothelial cell dysfunction, which reduces their response to vasodilators [19] and impairs critical regulation of blood flow [20,21]. Blood microvessels isolated from AD patients have been shown to be directly toxic to cultured neurons [22]. Examination of AD brains reveals white matter lesions resembling those observed after ischemia [23], and compromised blood flow can lead to the pathological synaptic changes characteristic of AD [6,24]. All these studies suggest that some of the neuronal loss in AD could be secondary to circulatory deficiencies [6,8,25].

#### *Epidemiological studies*

In addition to the profound cerebrovascular dysfunction presented in AD brain, epidemiological studies link vascular disease with AD [26]. Cardiovascular disease is associated with more rapid cognitive decline in AD patients [27] and indicators or risk factors for vascular disease such as atherosclerosis [28,29], stroke [30,31], heart disease [31] and atrial fibrillation [27,28], among others, correlate well with disease pathology in AD. More than twenty vascular-related factors that provoke a decrease in cerebral perfusion have been identified as risk factors for AD [32] and an increased number of vascular risk factors are related to a higher probability of suffering AD [30,33].

#### *A $\beta$ and abnormal hemostasis*


Apart from all these studies supporting the idea of an important vascular contribution to AD, the deposition of A $\beta$  in the vessels forming CAA may act as a decisive factor to the severity of the vascular pathology. CAA not only thickens the wall of the vessels, contributing to the disturbance in the blood flow [6] but also affects and promotes the degeneration of the cells of the vascular wall as well as promotes inflammation [34]. CAA correlates strongly with the severity of dementia and may play an important role in the pathogenesis of this disease [35]. Also, A $\beta$  may affect the blood directly as it can augment blood platelet aggregation *in vitro* and increase thrombosis [36,37]. This result is supported by the observed protective effect of anti-platelet therapy against AD disease progression [38,39]. In fact, abnormal hemostasis in this disorder is suggested by elevated levels in AD patients of molecules such as plasminogen activator inhibitor (PAI-1) [40], von Willebrand factor [40,41], fibrin degradation products [41] and thrombin [42]. Interestingly, patients with atrial fibrillation and with a consequent increase in the prothrombotic state, present a significant increase in the risk of

developing AD [27,28] and furthermore, those patients treated with anticoagulants present less dementia and cognitive impairment [43]. These data also indicate the importance of the control of the hemostasis in AD.

#### **Fibrinogen in AD**

Fibrin is the primary protein component of a blood clot. Its inactive precursor, fibrinogen, circulates in the blood as a large complex molecule of 340 kDa [44]. Under normal circumstances, fibrinogen is excluded from the brain by the blood-brain barrier (BBB). However, the cerebrovascular pathology that takes place in the AD brain may affect the proper function of the BBB that tightly controls the communication between the circulation and the central nervous system and protects the brain's microenvironment from macromolecules in circulation [18]. BBB damage has been reported in AD transgenic mice [45-47] as well as in human AD patients [48-50] and fibrinogen gains access to the brain parenchyma and accumulates over time as AD pathology progresses [47,51,52]. Also, an increase in fibrinogen levels has been reported to be associated with risk for dementia and AD [53-55]. In addition, the plasmin/tissue plasminogen activator (tPA) system is affected in AD as proteolytic activity of plasmin is decreased in the AD brain [56] and, PAI-1, one of the inhibitors of tPA, is up-regulated in AD mice [57] and in the cerebrospinal fluid of AD patients [58]. With increased permeability of the BBB and diminished activity of fibrinolysis pathway components, the AD brain presents a situation that tends to accumulate fibrin. As fibrin(ogen) accumulation causes damage when present in the extravascular space [59], and induces pathology in the nervous system [60], the role of fibrin(ogen) deposition in AD needs further study.

An effective method to study the role of fibrinogen deposition in the cerebrovascular dysfunction in AD is by using two complementary approaches: genetic and pharmacologic modulation of fibrinogen and plasminogen levels in AD mice. For decreasing the fibrinogen levels, AD mice (TgCRND8, [13]) were crossed with fibrinogen-deficient mice [61]. Once mice that carried only one fibrinogen gene were generated, neurovascular damage and BBB permeability were compared with their AD littermates by measuring the degree of Evans Blue dye extravasation. AD mice with only one fibrinogen gene had a significant decrease in Evans blue extravasation compared to AD littermates indicating that the decrease in fibrinogen in these mice lessens pathology in the cortex and hippocampus (Fig. 1) [47]. To reduce circulating levels of fibrinogen pharmacologically, we treated AD mice with the fibrinogen inhibitor anicrod, a thrombin-like protease derived from the venom of the Malayan pit viper *Agkistrodon rhodostoma* (Fig. 1). This protease cleaves fibrinogen releasing fibrinopeptide A but not B and therefore prevents fibrinogen polymerization and crosslinking and allows its degradation and removal [62,63]. The treatment with anicrod provokes a reduction in



**Fig. 1.** Schematic representation of the pathways leading to fibrin formation and degradation. When fibrinogen is cleaved by the protease thrombin, the fibrinopeptides A and B are released and the fibrinogen dimers non-covalently polymerize to form protofibrils, which then undergo crosslinking and branch to form an insoluble network of fibrils or a 'fibrin clot'. This clot network incorporates platelets to functionally impede blood flow and arrest hemorrhage at sites of vascular injury. Fibrin is naturally degraded by plasmin, which is generated from plasminogen after it is cleaved by tPA. Modulation of fibrinogen levels by using anicrod to decrease the levels of fibrinogen in the blood or tranexamic acid to specifically block conversion of plasminogen into plasmin, influences the degree of pathology in AD. FDPs, fibrin degradation products. Representation of the fibrinogen molecule adapted from ref. [44].

fibrinogen levels by 50–75% in the mouse circulation [47] and this fibrinogen depletion in AD mice was accompanied by an improvement in the vascularization, a significant reduction in BBB permeability and an important decrease in microgliosis when compared with saline-treated mice [47].

We hypothesized that the reduction of plasmin activity in AD should have effects opposite to that of reduction in fibrinogen levels and would promote neurovascular pathology. For modulating the plasminogen levels in AD, plasminogen deficient mice [64,65] were crossed with AD mice. The loss of one plasminogen allele in AD mice produced a significant increase in Evans blue extravasation, indicating an exacerbation in the neurovascular pathology in the cortex and hippocampus [47]. When working with congenital knockout mice, there is always the possibility of developmental defects. Therefore and as previously done with the studies reducing fibrinogen in AD mice, we also targeted plasminogen using a pharmacologic approach to complement our genetic analyses. To disrupt fibrinolysis pharmacologically, we treated AD mice with the plasmin inhibitor, tranexamic acid (Fig. 1). Suppressing plasmin activity using this method led to an expected increase in fibrin deposition in the brain of AD mice compared with saline-treated AD mice and these elevated levels in fibrin were accompanied by an

increase in inflammation, neurovascular damage and BBB permeability [47].

## Conclusion

Alzheimer's disease is a complex neurodegenerative disorder that has a strong vascular component in its pathology. Leakage of fibrinogen into the AD mouse brain is abnormal and aggravates the AD pathology. The relationship between fibrin(ogen) and A $\beta$  is under investigation and this molecule could play an important role in the progression of this disease.

## Acknowledgments

This work was supported by the National Institutes of Health (NS50537); the Alzheimer's Drug Discovery Foundation (281203); the Alzheimer's Association (IIRG-04-1356); the Litwin Foundation; the Blanchette Hooker Rockefeller Fund, and the May and Samuel Rudin Family Foundation. M. C-C is a postdoctoral fellow in The Rockefeller University Women & Science Fellowship Program. We thank members of the Strickland laboratory for helpful discussions. Correspondence should be addressed to Sidney Strickland (e-mail: Strickland@rockefeller.edu).

## Disclosure of Conflict of Interests

The authors state that they have no conflict of interests.

## References

- Cummings JL, Cole G. Alzheimer disease. *JAMA* 2002; **287**: 2335–8.
- Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. *Science* 2006; **314**: 781–4.
- Dawbarn D, Allen SJ. *Neurobiology of Alzheimer's Disease: (Molecular and Cellular Neurobiology)*, 3rd edn. Oxford, New York: Oxford University Press, 2007.
- Carlsson CM. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions. *J Alzheimers Dis* 2008; **15**: 327–38.
- Doraiswamy PM, Xiong GL. Pharmacological strategies for the prevention of Alzheimer's disease. *Expert Opin Pharmacother* 2006; **7**: 1–10.
- Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. *Prog Neurobiol* 2001; **64**: 575–611.
- Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. *Nat Rev Neurosci* 2004; **5**: 347–60.
- de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. *Lancet Neurol* 2004; **3**: 184–90.
- Thal DR, Griffin WS, Braak H. Parenchymal and vascular A $\beta$ -deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. *J Cell Mol Med* 2008; **12**: 1848–62.
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002; **297**: 353–6.
- Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. *Nature* 1995; **373**: 523–7.
- Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A $\beta$  elevation, and amyloid plaques in transgenic mice. *Science* 1996; **274**: 99–102.
- Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. *J Biol Chem* 2001; **276**: 21562–70.
- Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. *Rejuvenation Res* 2006; **9**: 77–84.
- Nitsch RM, Hock C. Targeting beta-amyloid pathology in Alzheimer's disease with A $\beta$  immunotherapy. *Neurotherapeutics* 2008; **5**: 415–20.
- Vasilevko V, Cribbs DH. Novel approaches for immunotherapeutic intervention in Alzheimer's disease. *Neurochem Int* 2006; **49**: 113–26.
- Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol* 2007; **8**: 101–12.
- Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. *Pharmacol Rev* 2005; **57**: 173–85.
- Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. *Am J Physiol Heart Circ Physiol* 2002; **283**: H315–23.
- Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. *Neurobiol Dis* 2002; **9**: 61–8.
- Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. *Stroke* 2003; **34**: 335–7.
- Grammas P, Reimann-Philipp U, Weigel PH. Cerebrovasculature-mediated neuronal cell death. *Ann N Y Acad Sci* 2000; **903**: 55–60.
- Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. *Ann Neurol* 1986; **19**: 253–62.
- Wen Y, Yang S, Liu R, Simpkins JW. Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. *Brain Res* 2004; **1022**: 30–8.
- Vinters HV, Wang ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. *Brain Pathol* 1996; **6**: 179–95.
- Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: How to move forward? *Neurology* 2009; **72**: 368–74.
- Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JC, Munger R, Lyketsos CG. Vascular factors predict rate of progression in Alzheimer disease. *Neurology* 2007; **69**: 1850–8.
- Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. *Ann N Y Acad Sci* 2000; **903**: 457–65.
- Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. *Arterioscler Thromb Vasc Biol* 2003; **23**: 2055–62.
- Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R. Stroke and the risk of Alzheimer disease. *Arch Neurol* 2003; **60**: 1707–12.
- de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer's disease? *Neurol Res* 2006; **28**: 637–44.
- de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. *Stroke* 2002; **33**: 1152–62.
- Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. *Neurology* 2005; **65**: 545–51.
- Rensink AA, de Waal RM, Kremer B, Verbeek MM. Pathogenesis of cerebral amyloid angiopathy. *Brain Res Brain Res Rev* 2003; **43**: 207–23.
- Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. *Neurobiol Aging* 2004; **25**: 589–97.
- Wolozin B, Maheshwari S, Jones C, Dukoff R, Wallace W, Racchi M, Nagula S, Shulman NR, Sunderland T, Bush A. Beta-amyloid augments platelet aggregation: reduced activity of familial angiopathy-associated mutants. *Mol Psychiatry* 1998; **3**: 500–7.
- Kowalska MA, Badellino K. beta-Amyloid protein induces platelet aggregation and supports platelet adhesion. *Biochem Biophys Res Commun* 1994; **205**: 1829–35.
- Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. *J Neurosci* 2000; **20**: 5709–14.
- Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, Paul SM, Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic A $\beta$ 42 by inhibiting Rho. *Science* 2003; **302**: 1215–7.
- Mari D, Parnetti L, Coppola R, Bottasso B, Reboldi GP, Senin U, Mannucci PM. Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. *Thromb Haemost* 1996; **75**: 216–8.
- Gupta A, Watkins A, Thomas P, Majer R, Habubi N, Morris G, Pansari K. Coagulation and inflammatory markers in Alzheimer's and vascular dementia. *Int J Clin Pract* 2005; **59**: 52–7.
- Grammas P, Samany PG, Thirumangalakudi L. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. *J Alzheimers Dis* 2006; **9**: 51–8.

- 43 Barber M, Tait RC, Scott J, Rumley A, Lowe GD, Stott DJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. *J Thromb Haemost* 2004; **2**: 1873–8.
- 44 Weisel JW. Fibrinogen and fibrin. *Adv Protein Chem* 2005; **70**: 247–99.
- 45 Ujiiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood–brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. *Microcirculation* 2003; **10**: 463–70.
- 46 Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. *Am J Pathol* 2005; **167**: 527–43.
- 47 Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. *J Exp Med* 2007; **204**: 1999–2008.
- 48 Kalaria RN. The blood–brain barrier and cerebrovascular pathology in Alzheimer's disease. *Ann N Y Acad Sci* 1999; **893**: 113–25.
- 49 Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood–brain barrier impairment in Alzheimer disease: stability and functional significance. *Neurology* 2007; **68**: 1809–14.
- 50 Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood–brain barrier leakage in Alzheimer's disease. *Neurobiol Aging* 2007; **28**: 977–86.
- 51 Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood–brain barrier. *Eur J Clin Invest* 2002; **32**: 360–71.
- 52 Ryu JK, McLarnon JG. A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. *J Cell Mol Med* 2008. Epub ahead of print. PMID:18657226.
- 53 van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. *Stroke* 2005; **36**: 2637–41.
- 54 Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, Ha SA, Kim JR, Kim JW. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. *BMC Neurol* 2007; **7**: 14.
- 55 Xu G, Zhang H, Zhang S, Fan X, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. *Int J Clin Pract* 2008; **62**: 1070–5.
- 56 Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. *EMBO Rep* 2000; **1**: 530–5.
- 57 Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. *J Neurosci* 2003; **23**: 8867–71.
- 58 Sutton R, Keohane ME, VanderBerg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. *Blood Coagul Fibrinolysis* 1994; **5**: 167–71.
- 59 Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. *Cell* 1996; **87**: 709–19.
- 60 Adams RA, Passino M, Sachs BD, Nuriel T, Akassoglou K. Fibrin mechanisms and functions in nervous system pathology. *Mol Interv* 2004; **4**: 163–76.
- 61 Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. *Genes Dev* 1995; **9**: 2020–33.
- 62 Bell WR, Shapiro SS, Martinez J, Nossel HL. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (*A. rhodostoma*) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. *J Lab Clin Med* 1978; **91**: 592–604.
- 63 Burkhardt W, Smith GF, Su JL, Parikh I, LeVine H III. Amino acid sequence determination of ancrod, the thrombin-like alpha-fibrinogenase from the venom of *Akistrodon rhodostoma*. *FEBS Lett* 1992; **297**: 297–301.
- 64 Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. *Circulation* 1995; **92**: 2585–93.
- 65 Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. *Genes Dev* 1995; **9**: 794–807.